Announcements

GSS Amended Appendix 4E and Audited Financial Report 30 June 2015

• Further expansion for EasyScreen™ Pathogen Detection products
• Distribution deals signed for Ireland and Poland
• Agreements support Genetic Signatures’ strategy of global market penetration and increased market share

Molecular diagnostics company Genetic Signatures (ASX: GSS) has announced that it has signed distribution deals for Ireland and Poland, further expanding the market reach for its EasyScreen™ Products.

Full Press Release

GSS Appendix 4C 30 June 2015

• First regulatory step towards full product suite commercialisation in US
• Enables US sales of the kit to broad customer base

Molecular diagnostics company Genetic Signatures (ASX: GSS) today announced it has received a United States Food and Drug Administration (FDA) listing for it’s clinical sample concentrator, the EasyScreen™ Sample Processing Kit (SP001). The FDA listing means that the company can legally sell it’s EasyScreen™ Sample Processing Kit in the US, a first step in the further release of other EasyScreen™ products planned for US markets.

Full Press Release

Genetic Signatures CFO Rob Birrell recently presented at the 11th Bioshares Biotech Summit in Queenstown held on Friday 17- Saturday 18 July, 2015. The presentation featured in a session titled New IPOs, with a focus on biotech companies that have listed in the last 12 months, their respective IPO experiences and the value propositions of the newly listed companies. The presentation slides can be downloaded here

About the Bioshares Biotech Summit: The Summit is organised by Bioshares, Australia’s leading independent biotech investment publication. Attendees include biotech executives, fund managers and, retail investors.

25th May 2015 – GSS Non-Deal Roadshow Presentation

GSS Appendix 4C 31 March 2015

Press Release

Press Release